In addition to VIP236, Vincerx’s pipeline has a clinical-stage cyclin-dependent kinase-9 (CDK9) inhibitor program, VIP152 2, and two preclinical ADC candidates that exemplify the differentiated ...

Prelude’s CEO, Kris Vaddi, Ph.D., emphasized the significance of PRT2527’s results while outlining future priorities. “These findings confirm our hypothesis that a selective and potent CDK9 ...

To protect its technology and pipeline ... multi-kinase inhibitor designed to block a specific leukemic stem cell target (CK1α) as well as super enhancer targets (CDK7/CDK9) preventing ...

The company is also advancing SLS009, a small molecule CDK9 inhibitor with promising potential in treating acute myeloid leukemia. The press release includes forward-looking statements regarding ...